Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, August 08, 2024
WuXi Biologics and Medigene AG announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors.
read more
Tuesday, February 12, 2019
WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
read more
Wednesday, September 21, 2022
WuXi Biologics announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
read more
Tuesday, October 19, 2021
WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai.
read more
Tuesday, November 16, 2021
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia's Navy Yard. The new facility, which includes 140,000 ...
read more
WuXi AppTec Co. Ltd. has announced that the small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility located in Jinshan Shanghai, which is part of its subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd...
read more
WuXi AppTec has announced that its pharmaceutical facilities and analytical and stability testing facilities in Shanghai passed the European Medicines Agency (EMA)inspection for GMP compliance, with "no critical and no major findings." This is the ...
read more
WuXi AppTec announced the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines.
read more
Tuesday, January 20, 2026
WuXi AppTec announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP's ...
read more
WuXi AppTec reported first-quarter 2026 total revenue of RMB 12.44 billion, an increase of 28.8% year over year, with revenue from continuing operations up 39.4%.
read more
WuXi AppTec Co. Ltd. has started construction of a state-of-the-art integrated biologics solution center at the company's headquarters in Shanghai. The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, ...
read more
WuXi AppTec (WuXi), recently opened their new 150,000-square-foot biomanufacturing facility in an event attended by Pennsylvania Lieutenant Governor Mike Stack and WuXi AppTec Chairman and Chief Executive Officer, Dr. Ge Li. The new facility is WuXi...
read more
WuXi AppTec an open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, has announced the opening of its branch office in Seoul, South Korea.
read more
Monday, September 09, 2019
WuXi AppTec announced its launch of a novel DNA Encoded Library service package, providing efficient hit finding services to expedite early drug discovery and bring new medicines to patients faster.
read more
WuXi AppTec an open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, has announced that WuXi Lab Testing Division (LTD)'s late-and commercial-stage analytical and ...
read more